Last reviewed · How we verify

NCT07522736

Intrathecal Dexmedetomidine With Bupivacaine, in Patients Undergoing Knee Orthopedic Surgery

Recruiting now NA Last updated 13 April 2026
What this trial tests

NA trial testing Dexmedetomidine 4 μg in Intrathecal Dexmedetomidine in 120 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
30 August 2026
30 August 2026

Quick facts

Lead sponsorCairo University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment120
Start date1 March 2025
Primary completion30 August 2026
Estimated completion30 August 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 18 to 65, any sex, with Intrathecal Dexmedetomidine or Bupivacaine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare the duration of analgesia (as the primary outcome) and adverse effects (as the secondary outcome) after intrathecal administration of dexmedetomidine with hyperbaric bupivacaine to patients undergoing knee orthopedic surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intrathecal Dexmedetomidine

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07522736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing